ECSP14024561A - Métodos de monitoreo terapéutico de profármacos de ácido fenilacético - Google Patents

Métodos de monitoreo terapéutico de profármacos de ácido fenilacético

Info

Publication number
ECSP14024561A
ECSP14024561A ECIEPI201424561A ECPI201424561A ECSP14024561A EC SP14024561 A ECSP14024561 A EC SP14024561A EC IEPI201424561 A ECIEPI201424561 A EC IEPI201424561A EC PI201424561 A ECPI201424561 A EC PI201424561A EC SP14024561 A ECSP14024561 A EC SP14024561A
Authority
EC
Ecuador
Prior art keywords
propharmacs
phenylacetic acid
monitoring methods
therapeutic monitoring
pagn
Prior art date
Application number
ECIEPI201424561A
Other languages
English (en)
Spanish (es)
Inventor
Masoud Mokhtarani
Bruce Scharschmidt
Original Assignee
Hyperion Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49380684&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP14024561(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hyperion Therapeutics Inc filed Critical Hyperion Therapeutics Inc
Publication of ECSP14024561A publication Critical patent/ECSP14024561A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6806—Determination of free amino acids
    • G01N33/6812—Assays for specific amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
ECIEPI201424561A 2012-04-20 2014-10-27 Métodos de monitoreo terapéutico de profármacos de ácido fenilacético ECSP14024561A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261636256P 2012-04-20 2012-04-20
PCT/US2012/054673 WO2013158145A1 (en) 2012-04-20 2012-09-11 Methods of therapeutic monitoring of phenylacetic acid prodrugs

Publications (1)

Publication Number Publication Date
ECSP14024561A true ECSP14024561A (es) 2015-09-30

Family

ID=49380684

Family Applications (1)

Application Number Title Priority Date Filing Date
ECIEPI201424561A ECSP14024561A (es) 2012-04-20 2014-10-27 Métodos de monitoreo terapéutico de profármacos de ácido fenilacético

Country Status (25)

Country Link
US (4) US9561197B2 (enExample)
EP (2) EP2846791B1 (enExample)
JP (3) JP6234436B2 (enExample)
KR (2) KR102264579B1 (enExample)
CN (3) CN113995743A (enExample)
AU (3) AU2012377389A1 (enExample)
BR (1) BR112014026138A2 (enExample)
CL (2) CL2014002807A1 (enExample)
CY (1) CY1118838T1 (enExample)
DK (1) DK2846791T3 (enExample)
EC (1) ECSP14024561A (enExample)
ES (2) ES2623470T3 (enExample)
HR (1) HRP20170651T1 (enExample)
HU (1) HUE032726T2 (enExample)
IL (2) IL235127A (enExample)
LT (1) LT2846791T (enExample)
MX (1) MX365302B (enExample)
PL (1) PL2846791T3 (enExample)
PT (1) PT2846791T (enExample)
RS (1) RS55870B1 (enExample)
SG (2) SG10201608749UA (enExample)
SI (1) SI2846791T1 (enExample)
SM (1) SMT201700219T1 (enExample)
WO (1) WO2013158145A1 (enExample)
ZA (1) ZA201407597B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3263102A1 (en) 2011-09-30 2018-01-03 Horizon Therapeutics, LLC Methods of therapeutic monitoring of nitrogen scavenging drugs
BR112014026138A2 (pt) 2012-04-20 2017-06-27 Hyperion Therapeutics Inc métodos de monitoramento terapêutico de pró-fármacos de ácido fenilacético
HUE036133T2 (hu) 2012-11-21 2018-06-28 Horizon Therapeutics Llc Eljárások hepatikus enkefalopátia kezelésére szolgáló nitrogénelvonó gyógyszerek beadására és értékelésére
PL2986325T3 (pl) 2013-10-14 2020-03-31 Immedica Pharma Ab Sposoby leczenia zaburzenia cyklu mocznikowego
ES2748294T3 (es) * 2014-06-04 2020-03-16 Immedica Pharma Ab Métodos para tratar trastornos del ciclo de la urea con el fin de prevenir crisis hiperamonémicas controlando los niveles de amoniaco en sangre
US9914692B2 (en) 2016-05-25 2018-03-13 Horizon Therapeutics, Llc Procedure for the preparation of 4-phenyl butyrate and uses thereof
US20190076383A1 (en) * 2017-09-08 2019-03-14 Horizon Therapeutics, Llc Methods for treating urea cycle disorders
US10668040B2 (en) 2017-09-11 2020-06-02 Horizon Therapeutics, Llc Treatment of urea cycle disorders in neonates and infants

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4284647A (en) 1980-03-31 1981-08-18 The Johns Hopkins University Process for waste nitrogen removal
US4457942A (en) 1982-08-20 1984-07-03 Brusilow Saul W Process for waste nitrogen removal
US5635532A (en) 1991-10-21 1997-06-03 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Compositions and methods for therapy and prevention of pathologies including cancer, AIDS and anemia
US5879657A (en) 1993-03-30 1999-03-09 The Dupont Merck Pharmaceutical Company Radiolabeled platelet GPIIb/IIIa receptor antagonists as imaging agents for the diagnosis of thromboembolic disorders
WO1996024571A1 (en) 1995-02-07 1996-08-15 Brusilow Saul W Triglycerides and ethyl esters of phenylalkanoic acid and phenylalkenoic acid useful in treatment of various disorders
US6219567B1 (en) 1999-06-21 2001-04-17 Cardiox Corporation Monitoring of total ammoniacal concentration in blood
US20030195255A1 (en) 2002-04-12 2003-10-16 Summar Marshall L. Method for treating hepatic encephalopathies
US20040229948A1 (en) 2002-04-12 2004-11-18 Summar Marshall L. Method for preventing hepatic encephalopathic episodes
US20050273359A1 (en) 2004-06-03 2005-12-08 Young David E System and method of evaluating preoperative medical care and determining recommended tests based on patient health history and medical condition and nature of surgical procedure
PT2319581E (pt) 2004-11-26 2015-06-30 Ucl Business Plc Composições compreendendo ornitina e fenilacetato ou fenilbutirato para tratamento de encefalopatia hepática
US20060135612A1 (en) 2004-12-17 2006-06-22 U.S. Department Of Veterans Affairs Method of ameliorating or abrogating the effects of a neurodegenerative disorder, such as amyotrophic lateral sclerosis (ALS), by using a HDAC inhibiting agent
US20070004805A1 (en) 2005-07-01 2007-01-04 Navinta Llc Process for preparation of liquid dosage form containing sodium 4-phenylbutyrate
US20100016207A1 (en) 2005-11-10 2010-01-21 Wurtman Richard J Methods and Compositions for Raising Levels and Release of Gamma Aminobutyric Acid
US8094521B2 (en) 2007-02-28 2012-01-10 Nightingale Products LLC Caregiver personal alert device
GB2451259B (en) * 2007-07-25 2011-07-20 Gp Acoustics Loudspeaker
US9078864B2 (en) 2008-01-08 2015-07-14 Akthelia Pharmaceuticals Agonists for antimicrobial peptide systems
GB2465250B (en) * 2008-08-29 2011-01-26 Ucyclyd Pharma Inc Dosing and monitoring patients on nitrogen-scavenging drugs
WO2009134460A1 (en) * 2008-04-29 2009-11-05 Hyperion Therapeutics Methods of treatment using ammonia-scavenging drugs
JP5577341B2 (ja) * 2008-08-29 2014-08-20 ハイペリオン セラピューティクス, インコーポレイテッド アンモニア捕捉薬を使用する処置方法
CN102481269B (zh) * 2009-05-11 2015-10-07 博格有限责任公司 包含辅酶q10的药物组合物及其制备方法
EP2954780A1 (en) 2009-07-24 2015-12-16 Baylor College Of Medicine Methods of modulation of branched chain acids and uses thereof
JP6049619B2 (ja) 2010-08-31 2016-12-21 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル ナノヒドロキシアパタイトを含む多孔質多糖足場、及び骨形成のための使用
EP3263102A1 (en) 2011-09-30 2018-01-03 Horizon Therapeutics, LLC Methods of therapeutic monitoring of nitrogen scavenging drugs
BR112014026138A2 (pt) * 2012-04-20 2017-06-27 Hyperion Therapeutics Inc métodos de monitoramento terapêutico de pró-fármacos de ácido fenilacético
HUE036133T2 (hu) 2012-11-21 2018-06-28 Horizon Therapeutics Llc Eljárások hepatikus enkefalopátia kezelésére szolgáló nitrogénelvonó gyógyszerek beadására és értékelésére

Also Published As

Publication number Publication date
PT2846791T (pt) 2017-05-25
EP2846791B1 (en) 2017-02-08
JP6234436B2 (ja) 2017-11-22
CN104540507A (zh) 2015-04-22
CL2017001375A1 (es) 2018-01-05
PL2846791T3 (pl) 2017-07-31
EP3222275B1 (en) 2020-06-24
AU2019201811B2 (en) 2020-07-09
DK2846791T3 (en) 2017-03-27
EP2846791A4 (en) 2015-08-19
JP6637941B2 (ja) 2020-01-29
JP2015514757A (ja) 2015-05-21
KR20150013170A (ko) 2015-02-04
ES2623470T3 (es) 2017-07-11
HK1243959A1 (en) 2018-07-27
AU2012377389A1 (en) 2014-10-30
EP2846791A1 (en) 2015-03-18
MX2014012694A (es) 2015-06-03
ZA201407597B (en) 2017-05-31
RS55870B1 (sr) 2017-08-31
CL2014002807A1 (es) 2015-02-27
WO2013158145A1 (en) 2013-10-24
AU2018200163B2 (en) 2018-12-20
HK1208380A1 (en) 2016-03-04
US9561197B2 (en) 2017-02-07
US20180263938A1 (en) 2018-09-20
SMT201700219T1 (it) 2017-05-08
SI2846791T1 (sl) 2017-06-30
HRP20170651T1 (hr) 2017-06-30
JP2018039830A (ja) 2018-03-15
US20180015058A1 (en) 2018-01-18
KR102264579B1 (ko) 2021-06-11
AU2019201811A1 (en) 2019-04-04
BR112014026138A2 (pt) 2017-06-27
AU2018200163A1 (en) 2018-02-01
EP3222275A1 (en) 2017-09-27
US20130281530A1 (en) 2013-10-24
HUE032726T2 (en) 2017-10-30
US20170266143A1 (en) 2017-09-21
IL255918A (en) 2018-01-31
CY1118838T1 (el) 2018-01-10
JP2019219413A (ja) 2019-12-26
WO2013158145A9 (en) 2014-05-01
LT2846791T (lt) 2017-04-10
CN111991383A (zh) 2020-11-27
CN113995743A (zh) 2022-02-01
SG10201608749UA (en) 2016-12-29
IL235127A (en) 2017-12-31
KR20190116552A (ko) 2019-10-14
SG11201406745VA (en) 2014-12-30
IL255918B (en) 2019-06-30
ES2807951T3 (es) 2021-02-24
MX365302B (es) 2019-05-29

Similar Documents

Publication Publication Date Title
EP3875959B1 (en) DETECTION OF C-PEPTIDES BY MASS SPECTROMETRY
BR112014029372A2 (pt) medição do corpo
MY167585A (en) Disposable diaper
EP2764206A4 (en) Fast mud gas logging using tandem mass spectroscopy
UY34763A (es) Inhibidores de la agregación plaquetaria
DK2882850T3 (da) System for preparation of adipose-derived stem cells
EP2875051A4 (en) ANTIBODIES AGAINST SIGLEC-15
CY1118838T1 (el) Ηρν-100 για χρηση στην αντιμετωπιση διαταραχων κατακρατησης αζωτου
BR112013026467A2 (pt) análogos de prostaglandina conjugados com polímero
UY34213A (es) Medidor de pies
DK2485011T3 (da) Anordning til måling af afbøjningen af en genstand
BR112015012192A2 (pt) dispositivo de medição de comprimento
SMT201500057B (it) Uso della biotina per il trattamento della sclerosi multipla
MY166103A (en) Disposable diaper
BR112012016894A2 (pt) lactobacilos com ação antioxidante.
FI20116329L (fi) Mittauskohteen mittaus
EP2895528A4 (en) LIGNIN-poly (lactic acid) copolymers
FI20125887A7 (fi) Järjestely biosignaalin mittaamiseksi
CY1126140T1 (el) Ναλμεφενη για τη μειωση της καταναλωσεως αλκοολης σε συγκεκριμενους πληθυσμους στοχους
EP2872339A4 (en) SCOREBOARD
EP2671587A4 (en) PLASTER PREPARATION
UY34829A (es) Nueva dosificación y formulación
FI20110109A0 (sv) Cykliskt PSD pressningsförfarande
EP2931800A4 (en) PROCESS FOR PRODUCING EPOXYED POLYMERS
EP2907515A4 (en) SKIN PATCH